Loading...
Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
An available supply of intravenous immunoglobulin (IVIG) is essential for individuals with primary humoral immunodeficiency. A shortage in 1997 prompted the Food and Drug Administration (FDA) to revise guidelines for the licensure, production, and distribution of new IVIG products, including the sta...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer-Verlag
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3501191/ https://ncbi.nlm.nih.gov/pubmed/22968971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s15010-012-0323-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|